438452-29-0

Usage

Pyrrolidine Core

The central structure of the compound, which is a five-membered ring containing four carbon atoms and one nitrogen atom.

Carboxylic Acid Groups

The compound contains two carboxylic acid groups (-COOH) attached to the pyrrolidine core.

Ester Groups

The carboxylic acid groups are esterified, with one ester group being a 1-(1,1-dimethylethyl) and the other being a methyl group (-CH3).

Bromophenylsulfonyl Moiety

A 4-bromophenylsulfonyl group (-C6H4Br-SO2-) is attached to the pyrrolidine core through an oxygen atom.

Chiral Molecule

The compound is chiral, meaning it has a non-superimposable mirror image.

Asymmetric Carbon Centers

The compound has two asymmetric carbon centers, which contribute to its chirality.

Stereochemistry

The stereochemistry of the compound is (2S,4S)-, indicating the specific arrangement of the atoms around the asymmetric carbon centers.

Potential Applications

The unique structure and properties of the compound may have applications in pharmaceuticals, agrochemicals, or materials science due to its potential for specific interactions with biological systems.

Complex Structure

The compound's complex structure, with multiple functional groups and a chiral center, may contribute to its potential for specific interactions and applications.

Upstream product

• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 138-36-3 p-bromobenzene sulfonic acid 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 87250-97-3 2’-methyl-2’-propanyl (1S,4S)-3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylate 

Downstream Products

• 914835-38-4 1-t-butyl 2-methyl (2S,4R)-4-[(6-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 367258-59-1 4-(4-bromobenzenesulfonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 1020094-40-9 1-t-butyl 2-methyl (2S,4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 1000063-82-0 1-tert-butyl 2-methyl (2S,4R)-4-[(6-bromo-7-methoxy-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 1026208-17-2 1-tert-butyl 2-methyl (2S,4R)-4-(1-bromo-naphthalen-2-yloxy)-pyrrolidine-1,2-dicarboxylate 
• 921790-38-7 C₂₄H₃₃BrN₂O₈S 
• 1369482-19-8 1-tert-butyl 2-methyl (2S,4R)-4-{[4-(benzyloxy)-3-(prop-2-en-1-yl)quinolin-2-yl]oxy}pyrrolidine-1,2-dicarboxylate 
• 1206524-79-9 1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate 
• 1338650-03-5 tert-butyl (2S,4S)-4-{[(4-bromophenyl)sulfonyl]oxy}-2-{[(1R,2S)-2-ethenyl-1-(ethoxycarbonyl)cyclopropyl]carbamoyl}pyrrolidine-1-carboxylate 
• 874124-85-3 C₂₅H₃₂BrN₃O₉S₂ 
• 801282-60-0 C₂₃H₂₉BrN₂O₈S 
• 914835-77-1 methyl-N-[(hept-6-enyloxy)carbonyl]-L-norleucyl-(4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]-L-prolinate 
• 914836-16-1 methyl (2R,4S,7S)-7-butyl-6,9-dioxo-22-phenyl-3,4,6,7,8,9,12,13,14,15,16,17-dodecahydro-2H,11H-18,20-ethanediylidene-2,5-methanopyrido[4,3-κ][1,10,3,6]dioxadiazacyclohenicosine-4-carboxylate 
• 914835-64-6 methyl (4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]-L-prolinate chloride 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

no abstract published

Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof

The invention provides a process of preparing 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Compound I and pharmaceutically acceptable salts thereof.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

HCV NS3 PROTEASE INHIBITORS

The present invention relates to macro-cyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections

Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease

The discovery of GS-9451 is reported. Modification of the P3 cap and P2 quinoline with a series of solubilizing groups led to the identification of potent HCV NS3 protease inhibitors with greatly improved pharmacokinetic properties in rats, dogs and monke

A concise synthesis of the HCV protease inhibitor BILN 2061 and its P3 modified analogs

A concise synthesis of BILN 2061 was achieved through more efficient installation of P2 4-quinoline moiety via SN2 displacement of the β-OBs group located on the 4-hydroxyl proline intermediate, which was prepared from 4-α-hydroxyl proline analog via Mitsunobu reaction with inversion of stereochemistry. In addition, a short and practical synthesis for P3 unit is also described herein. Final assembly of four fragments for BILN 2061 was achieved with an overall yield of 58% in 4 steps from P1 to 15a. Furthermore several analogs of BILN 2061 (WX-1-WX-5) containing modifications on P3 unit were synthesized successfully using the same synthetic route as described for the parent inhibitor BILN 2061. Copyright

ORGANIC COMPOUNDS AND THEIR USES

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

ANTIVIRAL PHOSPHINATE COMPOUNDS

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

HCV NS3 PROTEASE INHIBITORS

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.